Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H23N3O4.CH4O3S |
Molecular Weight | 417.477 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
InChI
InChIKey=DNTNDFLIKUKKOC-UHFFFAOYSA-N
InChI=1S/C16H23N3O4.CH4O3S/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18;1-5(2,3)4/h7-10H,2-6,11H2,1H3,(H4,17,18,19);1H3,(H,2,3,4)
Molecular Formula | C16H23N3O4 |
Molecular Weight | 321.3715 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Gabexate is a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role. Gabexate mesylate is a drug marketed only in Italy and Japan and it is considered an essential drug in the treatment of acute pancreatitis. Gabexate is marketed under the brand name REMINARON among others in Japan. It relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation.
It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3051 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9610382 |
5.0 mM [Ki] | ||
Target ID: CHEMBL1075230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9610382 |
0.1 mM [Ki] | ||
Target ID: CHEMBL2319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9610382 |
2.6 mM [Ki] | ||
Target ID: CHEMBL2000 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | REMINARON Approved UseThis medicine relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation.
It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation. |
|||
Primary | REMINARON Approved UseThis medicine relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation.
It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17351806
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: continuous intravenous infusion (600 mg)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12649382
The LPS-induced increase in TNF-a production by human monocytes was significantly inhibited by gabexate mesilate at a concentration of 1.0 x10(-3) M.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:28:45 GMT 2023
by
admin
on
Fri Dec 15 15:28:45 GMT 2023
|
Record UNII |
E3Q07L0649
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID0045591
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | |||
|
56974-61-9
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | |||
|
m5620
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL87563
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | |||
|
SUB02295MIG
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | |||
|
DBSALT002364
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | |||
|
6604561
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | |||
|
E3Q07L0649
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY | |||
|
100000087255
Created by
admin on Fri Dec 15 15:28:45 GMT 2023 , Edited by admin on Fri Dec 15 15:28:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |